Skip to main content
. 2009 Jan;32(1):3–8. doi: 10.2337/dc08-1206

Table 1.

Baseline characteristics of the study population

Aspirin Placebo
Total population
    n 19,326 19,390
    Age category (%)
        45–54 years 60.6 60.6
        55–64 years 29.2 29.2
        ≥65 years 10.2 10.1
    BMI category (%)
        <25.0 kg/m2 51.8 51.8
        25.0–29.9 kg/m2 30.8 31.0
        ≥30.0 kg/m2 17.4 17.2
    Ethnicity (%)
        White not of Hispanic origin 95.1 95.0
        African American 2.3 2.1
        Hispanic 1.0 1.1
        American Indian or Alaskan Native 0.3 0.2
        Asian or Pacific Islander 1.3 1.5
        Unknown (none of the above) 0.2 0.2
    Family history of diabetes (%)* 24.6 25.1
    Current smoker (%) 12.9 13.4
    Exercise ≥ once weekly (%) 42.4 41.8
    Alcohol consumption ≥ once weekly (%) 42.4 42.5
    History of hypertension (%) 24.9 24.7
    History of hyperlipidemia (%) 29.5 28.5
    Postmenopausal (%) 54.6 53.9
    Baseline use of hormone therapy (%) 41.6 40.9
Available baseline blood specimen
    n 13,595 13,572
    Total cholesterol (mmol/l) 5.41 (4.76–6.10) 5.38 (4.76–6.08)
    LDL cholesterol (mmol/l) 3.15 (2.60–3.74) 3.13 (2.60–3.72)
    HDL cholesterol (mmol/l) 1.35 (1.13–1.62) 1.35 (1.12–1.61)
    Total cholesterol–to–HDL cholesterol ratio 4.0 (3.2–4.9) 3.9 (3.2–4.9)
    Non-HDL cholesterol(mmol/l) 3.99 (3.33–4.72) 3.98 (3.34–4.68)
    A1C (%) 5.0 (4.8–5.2) 5.0 (4.8–5.2)
    hsCRP (mg/l) 2.0 (0.8–4.2) 2.0 (0.8–4.3)

Data are % or median (interquartile range).

*

Family history of diabetes in a first-degree relative (mother, father, sister, or brother).

Physical activity defined by number of episodes of vigorous physical activity per week.